Search Within

Matthew J Matasar

  1. "Center for Hematologic Malignancies"
  2. "Natasha Galasso"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (4)
Groups
  1. Center for Hematologic Malignancies (8)
  2. Department of Medicine (8)
  3. Hematologic Malignancies, Division of (8)
  4. Lymphoma (8)
  5. Survivorship Research (8)
  6. Bone Marrow Transplant (6)

More Groups

People
  1. Natasha Galasso (8)
  2. Andrew Zelenetz (7)
  3. Alison Moskowitz (6)
  4. Anita Kumar (6)
  5. Ariela Noy (6)
  6. Maria Palomba (6)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (2)
  4. 2020 (1)
  5. 2017 (2)
  6. 2015 (1)
Publications
  1. Blood (4)
  2. American Journal of Hematology (1)
  3. Blood Advances (1)
  4. British Journal of Haematology (1)
  5. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Hematology (5)
  2. American Society of Clinical Oncology (1)
  3. John Wiley & Sons (1)
  4. John Wiley & Sons, Inc. (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
    Journal Article

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
    Journal Article

    Mehta-Shah, N.; Lunning, M. A.; Moskowitz, A. J.; Boruchov, A. M.; Ruan, J.; Lynch, P.; Hamlin, P. A.; Leonard, J.; Matasar, M. J.; Myskowski, P. L.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era
    Journal Article

    Vardhana, S. A.; Sauter, C. S.; Matasar, M. J.; Zelenetz, A. D.; Galasso, N.; Woo, K. M.; Zhang, Z.; Moskowitz, C. H.
    British Journal of Haematology (2017)

    Fulltext@MSK | Save
  • Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era
    Meeting Abstract

    Vardhana, S. A.; Moskowitz, C. H.; Sauter, C. S.; Matasar, M. J.; Galasso, N.; Woo, K. M.; Zhang, Z. G.
    Blood (2015)

    Fulltext@MSK | Save